News
News from us and our partners
Tags
Topics
0 results
- News
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
- News
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
- News
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
- News
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
- News
Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion
- News
Mainstay Medical Announces Two-Year Outcomes from RESTORE Clinical Trial of ReActiv8®
- News
Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
- News
Biotalys Secures Product Registration in California for EVOCA®, Strengthening Regulatory Pathway for Its Lead Asset EVOCA NG
- News
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
- News
Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR
- News
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer
- News
Inventiva Appoints Chris Benecchi as Chief Operating Officer
- News
Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI in the European Union, the United Kingdom, Switzerland, Norway, and Iceland
- News
Galvanize Therapeutics® Announces the Latest Exploratory Evidence Suggesting Immune-Activating Potential of Aliya® PEF Energy
- News
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies